All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
TU55 binds to HLA-B*3501-Pol448-9. The TCR is derived from cytotoxic T lymphocyte clones isolated from Japanese HIV patients, specific for different HIV epitopes presented by locus-disparate MHCs, HLA-B*3501. The TU55 TCR variable domains consist of the same Vδ1 segment but different Vβ6.1 (TRBV6-1) segments. The affinity value of TU55 TCR for HLA-B*3501-Pol448-9 is about 0.27 μM. Extraordinarily, TU55 TCR has extremely low dissociation rates (i.e., long half-lives), at 0.0032 1/s.
There are currently no customer reviews or questions for Human anti-gag-pol T cell receptor (TU55), pCDTCR1 (TCR-YC0419). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION